Aviceda Therapeutics Announces Formation of Renowned European Clinical Advisory Board
Aviceda Announces First Patient Dosed in Part 2 of Trial Assessing AVD-104
Aviceda Announces Data from Part 1 of the Phase 2/3 SIGLEC Trial for AVD-104
Aviceda Announces First Patient Enrolled in Ph 2 GLYCO Trial Evaluating AVD-104
Aviceda Completes Enrollment in Part 1 of the SIGLEC Phase 2/3 U.S. Clinical Trial; Initiation of Part 2 Imminent
Aviceda Announces AVD-104, a Novel Glycomimetic Nanoparticle, Demonstrates Continued Clinical Safety in the Treatment of Geographic Atrophy Secondary to Macular Degeneration
Aviceda To Present at Major European Healthcare Conferences Highlighting AVD-104, a Novel Glyco-Mimetic Nanoparticle for the Treatment of Geographic Atrophy from Macular Degeneration
Aviceda Announces Podium Presentations on AVD-104, a Novel Glyco-Mimetic Nanoparticle for the Treatment of Geographic Atrophy from Macular Degeneration, at American Society of Retina Specialists (ASRS) and the OIS Retina Innovation Summit Meetings
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aviceda Therapeutics, a private clinical-stage biotech company focused on developing next generation immuno-modulators by harnessing the power of glycobiology to alleviate chronic, non-resolving inflammation, announced the dosing of its first patient with AVD-104 in its Phase 2 SIGLEC Trial today by Ashkan Abbey, MD of Texas Retina Associates in Dallas. This lead intravitreal asset is a novel glycan-coated nanoparticle, supported by a uniquely strong pre-clinical in vivo efficacy and safety profile, used for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). “I am honored to be the first to dose a new agent that we hope will usher in a generation of safe treatments for GA with better outcomes than were ever possible before,” said Dr. Abbey.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aviceda Therapeutics, a private clinical-stage biotech company focused on developing next-generation immunomodulators by harnessing the power of glycobiology to modulate the innate immune system and alleviate chronic, non-resolving inflammation with its lead ophthalmic asset, AVD-104, in late-stage clinical development for treatment of patients with geographic atrophy (GA), today announced the appointment of Patrick Johnson to its board of directors. Patrick is an accomplished business leader and entrepreneur with a proven track record of enabling pharmaceutical and biotechnology companies to maximize the value of their brands and realize the potential of their innovations.